Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide

Citation
T. Nishiyama et al., Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide, CLIN CANC R, 7(1), 2001, pp. 23-31
Citations number
43
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology
Journal title
CLINICAL CANCER RESEARCH
ISSN journal
1078-0432 → ACNP
Volume
7
Issue
1
Year of publication
2001
Pages
23 - 31
Database
ISI
SICI code
1078-0432(200101)7:1<23:IOBCUA>2.0.ZU;2-Z
Abstract
Recent investigations have demonstrated the efficacy of autologous dendriti c cells (DCs) pulsed with tumor antigens to generate tumor-specific CTLs ag ainst cancer cells. Melanoma antigens (MAGE) are a family of tumor-specific antigens shown to be expressed in various tumors, including bladder cancer s and melanoma, but not in normal tissues except for the testis, Because in vasive bladder cancers are frequently reported to express MAGE, we explored the possibility of establishing a new immunotherapeutic modality against a dvanced bladder cancer using autologous DCs pulsed with one of the MAGE-3 e pitope peptides (IMPKAGLLI), which is synthesized to bind specifically to H LA-A24, A MAGE-3-expressing bladder cancer cell line, FY, was newly establi shed from a lymph node metastasis of bladder cancer in a HLA-A24+ patient. The FY cell-specific CTL response was significantly higher when CTL was ind uced by autologous DCs pulsed with IMPKAGLLI than by FY cells alone or by n onpulsed DCs in vitro. A total of four HLA-A24+ patients with advanced MAGE -3+ bladder cancers were treated with s.c. injections of autologous DCs pul sed with IMPKAGLLI every 2 weeks for a minimum of 6 and a maximum of 18 tim es, Three of four patients showed significant reductions in the size of lym ph node metastases and/or liver metastasis, No significant untoward side ef fects were noted in these patients, This study indicated that, at sometime in the future, tumor-specific DC-based cancer immunotherapy may be useful a s an additional treatment modality against advanced bladder cancer.